News Quantified

MBRX – moleculin biotech, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Form PRE 14A Moleculin Biotech, Inc. For: Feb 05

Form 8-K Moleculin Biotech, Inc. For: Dec 17

Form 8-K Moleculin Biotech, Inc. For: Dec 15

Form 8-K Moleculin Biotech, Inc. For: Dec 09

Form 8-K Moleculin Biotech, Inc. For: Dec 09

Top News Gainers

3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS 41.2%

2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%

3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%

4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%

3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%

4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%

10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%

8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%

3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%

11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%

Top News Decliners

3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)] -50.0%

3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%

3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%

2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%

3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%

2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%

4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%

8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%

2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%

2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day